Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vinorelbine liposomal - Assertio Therapeutics

Next Previous
X
Search
Drug Profile

Vinorelbine liposomal - Assertio Therapeutics

Alternative Names: Alocrest; INX-0125; Liposomal vinorelbine; Sphingosomal vinorelbine; Vinorelbine liposomal; Vinorelbine tartrate injection; Vinorelbine-TCS

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Assertio Therapeutics; Talon Therapeutics
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-Hodgkin's lymphoma; Solid tumours

Highest Development Phases

  • Suspended Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Breast cancer; Lung cancer

Most Recent Events

  • 17 May 2016 No recent reports on development identified- Phase-I for Breast cancer & Lung cancer in Canada (IV)
  • 18 Jul 2013 Spectrum Pharmaceuticals acquires Talon Therapeutics' previous rights to liposomal vinorelbine
  • 18 Jul 2013 Phase-I clinical trials in Breast cancer in Canada (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top